The Unexpected Antitumor Properties of Our Pharmaceutical Agents
A special issue of Biology (ISSN 2079-7737).
Deadline for manuscript submissions: closed (30 April 2021) | Viewed by 404
Special Issue Editors
Interests: metabolism; cellular and molecular biology; cell signaling; cell death modality; epigenetic; cancer; immunity; oncoimmunology; anesthesiology; intensive care
Special Issues, Collections and Topics in MDPI journals
Interests: cancer; immunology; cell death; apoptosis; autophagy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Recently, some agents belonging to classical pharmacopeia such as analgesics, anti-inflammatory drugs, or antibiotics have shown an incredible antitumor response when used alone or in combination with conventional anticancer treatments. In addition, a surprising improvement in survival rates was observed after the injection of these agents during oncological surgery. Consequently, the benefits for patients are major. By potentiating the immune antitumor response, these agents offer the opportunity to improve patient outcomes without the side effects induced by traditional antitumor agents. Furthermore, adjuvant treatments during surgery can control residual tumor cells and decrease the risk of relapses. Finally, the possibility to employ some agents that are already marketed and whose features are well-known, enable the application of their antitumor properties immediately. Investigations into other agents that may induce the same effect and understand how these molecules interact with the immune system represent a challenging purpose. Clinicians need to be aware of the existence of such properties to give patients the maximum chance of recovery.
This Special Issue will gather original research, reviews, and commentaries dealing with preclinical and clinical discoveries in the use of classical agents as anti-cancer therapeutics, including techniques and methods that contributed to these breakthroughs.
Dr. Lucillia Bezu
Dr. Oliver Kepp
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- antitumor response
- immunology
- pharmacopeia
